Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS: JUNE ISSUE PUBLISHED
  • JUNE 2021 Issue has been successfully launched on 1 June 2021.

Abstract

COMPARATIVE STUDY OF SAFETY AND EFFICACY OF DERIPHYLLIN, DOXOPHYLLINE AND ACEBROPHYLLINE IN PATIENTS WITH STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Alisha Elsa Simon*, Anju Anne Xavier, Jeenu C. Benoy, Deepthi Mathew, Dr. Midhun M., Department of Pulmonary Medicine, Dr. Santhosh M. Mathew

 

ABSTRACT

Chronic Obstructive Pulmonary Disease (COPD), defined by chronic inflammation and destruction of the airways and lung parenchyma is usually associated with tobacco smoking or prolonged exposure to other noxious particles and gases. Methyl Xanthines have been used in combination for bronchodilation in COPD since many years. Doxophylline, a novel methyl xanthine is claimed to be therapeutically similar but with better safety. This study was designed to compare the safety and efficacy of Deriphylline, Doxophylline and Acebrophylline at doses commonly used in patients with stable COPD. The study was conducted in the department of Pulmonary Medicine in a tertiary care hospital. 120 patients were divided into three groups. Patients taken were already on LABA, LAMA and steroid MDI. Group 1 was administered Deriphylline 150 mg twice a day. In group 2 Doxophylline 200 mg was given twice a day and group 3 was administered Acebrophylline 100 mg twice a day. Before and after the study period, patients were evaluated for improvement in the symptoms by using CAT score, PEFR, SpO2 and by six minute walk test. Medication adherence and adverse events were analysed by MMAS-8 and Naranjos Causality Assessment Scale respectively. The obtained parameters were analysed and the results concluded that patients taking doxophylline 200 mg showed significant improvement in the pulmonary functions followed by acebrophylline and deriphylline. It can be concluded that Doxophylline has better safety and efficacy than Deriphylline and Acebrophylline in patients with stable COPD.

Keywords: Methyl xanthines, Deriphylline, Doxophylline, Acebrophylline, Phosphodiesterase inhibitors.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More